In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Ten investors take part in Foundation Medicine's $42.5mm Series B round; money added

Executive Summary

A year after capping off its Series A round at $33.5mm, Foundation Medicine Inc. (developed the FoundationOne genome analysis profiling system for personalized cancer treatment decision-making) has brought in an impressive $42.5mm through its Series B round. Returning investors Third Rock Ventures, Google Ventures, and Kleiner Perkins Caufield & Byers were joined by new buyers Deerfield Management, Casdin Capital, Redmile Group, Roche Venture Fund, and WuXi Corporate Venture Fund. Two undisclosed backers (a fund and a strategic investor) also participated.
Deal Industry
  • In Vitro Diagnostics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies